VCYT
VERACYTE, INC.
NASDAQ · Healthcare · Biotechnology · US
$39.80
−1.91%Sep 14, 2026, 20:05 UTC
Veracyte acquired Convergent Genomics, expanding its urology diagnostics portfolio with a urinary tumor DNA testing platform for bladder cancer care.
Aug 13, 2026, 07:26 UTC
Bank of America Corp DE increased its stake in Veracyte, Inc. by 14.7% during the first quarter, acquiring an additional 185,929 shares, according to its SEC filing.
Source:Aug 10, 2026, 03:30 UTC
Veracyte launched Prosigna and TrueMRD products, which are expected to contribute to future growth but are excluded from 2026 guidance.
Source:Aug 10, 2026, 03:30 UTC
Veracyte reported Q2 2026 results with 15% revenue growth, 23% adjusted EBITDA growth, and a 29.2% EBITDA margin, along with robust cash generation and no funded debt.
Source:Jul 30, 2026, 20:05 UTC
Veracyte reported its second quarter 2026 financial results, with total revenue of $150.3 million and testing revenue of $145.7 million, representing year-over-year increases of 15% and 19% respectively.
Source:Jun 1, 2026, 11:30 UTC
Veracyte launched the Prosigna Breast Test commercially in the United States.
Source: